{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-001711","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.334444+00:00","generated_at":"2026-05-28T05:38:39.148189+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"confidence":"high","headline":"Calidi refiles FY2023 financials to reflect 1-for-10 reverse stock split","bullets":["1-for-10 reverse stock split effective July 15, 2024, retroactively applied to FY2023 statements.","Exhibits incorporated by reference from December 12, 2024 S-1; no change to non-split information.","All other 2023 Annual Report information remains unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-001711","json":"https://secwatch.observer/filing/0001493152-25-001711.json","markdown":"https://secwatch.observer/filing/0001493152-25-001711.md","text":"https://secwatch.observer/filing/0001493152-25-001711.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000149315225001711/0001493152-25-001711-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000149315225001711/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:38:39.148189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}